iBio (IBIO)

Executive Summary

iBio is a US-based biotechnology company leveraging its proprietary AI-integrated drug discovery platform to develop next-generation antibody therapeutics for obesity and cardiometabolic diseases. The company aims to address the limitations of current GLP-1 therapies by creating more targeted, tolerable, and effective treatments. iBio's lead candidate, IBIO-600, is a novel antibody for overweight and obesity that recently entered a Phase 1 clinical trial (NCT07487376) in April 2026, with estimated completion in May 2027. The company is also advancing earlier-stage programs targeting cardiometabolic conditions, supported by its AI-driven approach that accelerates target identification and antibody engineering. iBio is publicly traded (NYSE: IBIO) with a current market capitalization of approximately $59 million, reflecting its early stage but significant potential in the high-growth obesity therapeutics market.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data for IBIO-600 in overweight/obesity55% success
• Q3 2026Corporate update or strategic partnership announcement40% success
• Q4 2026Preclinical data for next-generation cardiometabolic antibody program30% success